Intec Pharma Ltd. (NTEC) Analysts See $-0.30 EPS

November 10, 2018 - By Kristen Paramore

Intec Pharma Ltd. (NASDAQ:NTEC) Logo

Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.30 EPS on November, 21.They anticipate $0.10 EPS change or 25.00 % from last quarter’s $-0.4 EPS. After having $-0.34 EPS previously, Intec Pharma Ltd.’s analysts see -11.76 % EPS growth. The stock increased 0.17% or $0.01 during the last trading session, reaching $5.89. About 126,488 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has declined 49.01% since November 11, 2017 and is downtrending. It has underperformed by 64.63% the S&P500.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $195.70 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

More recent Intec Pharma Ltd. (NASDAQ:NTEC) news were published by: which released: “Intec Pharma: Lead Program Progressing, Continued Upside Ahead” on October 26, 2018. Also published the news titled: “Intec Pharma completes enrollment in Phase 3 trial of AP-CD/LD for the treatment of advanced PD” on October 22, 2018.‘s news article titled: “Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update” with publication date: November 09, 2018 was also an interesting one.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.